Verschuur H P, Wynne H J, Slootweg P J, van Langen J, Staal G E, Rijksen G, Hordijk G J
Department of Otorhinolaryngology, University Hospital Utrecht, The Netherlands.
Laryngoscope. 1995 Nov;105(11):1238-44. doi: 10.1288/00005537-199511000-00019.
Previous studies have shown that protein tyrosine (de)phosphorylation plays an important role in head and neck cancer. Protein-tyrosine kinases (PTK) and protein-tyrosine phosphatases (PTPase) activities in the cytosol of tumor tissue were significantly increased compared to normal tissue of cancer patients as well as controls. Additionally, the enzyme activities in normal tissue of tumor patients were significantly higher than enzyme activities in normal tissue of the control group. In this paper, we have correlated the cytosolic and membranous PTK and PTPase activity of tumor and nontumor tissue with several clinical and histological parameters known to influence the clinical outcome. Furthermore, we have analyzed the value of the enzyme activities as an independent predictor of clinical behavior and occurrence of second primary tumors. We confirmed our earlier observations that cytosolic and membranous PTK activities and cytosolic PTPase activities in tumor tissues are increased compared to activities in nontumor tissues and controls. Moreover, we also confirmed the findings of increased enzyme activities in nontumor tissues compared to findings in control tissues. This finding in histologically proven healthy mucosa is highly interesting because it indicates that these biochemical changes are obviously not (yet) translated into morphological changes. Significant differences were found in membranous PTK activity when the patients were grouped by sex, tumor localization, lymph node metastasis, and previous radiotherapy. During the follow-up period, no relation could be found between enzyme activities in tumor and/or nontumor tissues and disease-free interval or occurrence of second primary tumors.
先前的研究表明，蛋白质酪氨酸（去）磷酸化在头颈癌中起重要作用。与癌症患者的正常组织以及对照组相比，肿瘤组织胞质溶胶中的蛋白质酪氨酸激酶（PTK）和蛋白质酪氨酸磷酸酶（PTPase）活性显著增加。此外，肿瘤患者正常组织中的酶活性显著高于对照组正常组织中的酶活性。在本文中，我们将肿瘤组织和非肿瘤组织的胞质和膜PTK及PTPase活性与已知会影响临床结果的几个临床和组织学参数进行了关联。此外，我们分析了酶活性作为临床行为和第二原发性肿瘤发生的独立预测指标的价值。我们证实了我们早期的观察结果，即与非肿瘤组织和对照组相比，肿瘤组织中的胞质和膜PTK活性以及胞质PTPase活性增加。此外，我们还证实了与对照组织相比，非肿瘤组织中酶活性增加的发现。在组织学证实的健康黏膜中的这一发现非常有趣，因为它表明这些生化变化显然尚未转化为形态学变化。当按性别、肿瘤定位、淋巴结转移和既往放疗对患者进行分组时，膜PTK活性存在显著差异。在随访期间，未发现肿瘤和/或非肿瘤组织中的酶活性与无病生存期或第二原发性肿瘤的发生之间存在关联。
